Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plantago major extract is a botanical extract derived from the leaves of the *Plantago major* plant, commonly known as broadleaf plantain. It has a long history of use in traditional medicine, particularly in Indonesia, for treating inflammatory conditions, wounds, and infections. Scientific investigation has demonstrated that specific fractions of the extract, such as the n-hexane-insoluble fraction (IPM/IHF), possess potent anti-inflammatory and anti-rheumatoid arthritis properties. The mechanism of action involves the inhibition of cyclooxygenase-2 (COX-2) and the reduction of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Additionally, the extract suppresses leukocyte migration and inhibits osteoclast formation, which helps prevent joint destruction. Key bioactive constituents identified include ursolic acid, oleanolic acid, oleic acid, and linoleic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plantago major extract.